Similar articles

• Intermittent androgen deprivation: clinical experience and practical applications.

  Wright JL, Higano CS, Lin DW. Wright JL, et al. Urol Clin North Am. 2006 May;33(2):167-79, vi. doi: 10.1016/j.ucl.2005.12.013. Urol Clin North Am. 2006. PMID: 16631455 Review.
• [Hormonal treatment of cancer of the prostate: review and present status].

  Ganzer R, Wieland WF, Bach T, Rössler W, Blana A. Ganzer R, et al. Dtsch Med Wochenschr. 2007 Jan 26;132(4):161-6. doi: 10.1055/s-2007-959305. Dtsch Med Wochenschr. 2007. PMID: 17230333 Review. German. No abstract available.
• Advanced prostate cancer. Hormonal treatment.

  de la Haba-Rodríguez J. de la Haba-Rodríguez J. Tunis Med. 2005 Dec;83 Suppl 12:71-3. Tunis Med. 2005. PMID: 16430072 No abstract available.
• [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].

  Matveev BP, Bukharkin BV. Matveev BP, et al. Vopr Onkol. 1998;44(5):537-40. Vopr Onkol. 1998. PMID: 9884710 Review. Russian.
• Chemotherapy and prostate cancer.

  Dacker R. Dacker R. Radiol Technol. 1997 Jan-Feb;68(3):194-5. Radiol Technol. 1997. PMID: 9008013 No abstract available.